Skip to main content
. 2020 Feb 13;196(9):779–786. doi: 10.1007/s00066-020-01594-z

Fig. 1.

Fig. 1

Flow chart depicting the enrollment process. Modified CROSS neoadjuvant chemoradiotherapy plus surgery versus surgery alone for esophageal or junctional cancer (CROSS trial), SAKK Swiss Group for Clinical Cancer Research phase II trial (SAKK 75/08), XELOX capecitabine and oxaliplatin, EOX epirubicin, oxaliplatin and capecitabine